JanOne has executed a manufacturing agreement with the contract development and manufacturing organization (CDMO) CoreRx for the formulation and manufacturing of TV1001SR, a treatment for Peripheral Artery Disease (PAD). PAD affects over 8.5 million people in the U.S and there are currently no direct treatments for PAD on the market today. Research Market Future (MRFR) values the PAD market at $3.47 billion in the U.S. by 2023.   “CoreRx’s extensive clinical development experience ...